Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MA › Westfield › NPI 1700816048
Hospital

Baystate Noble Hospital Corporation

Baystate Noble Hospital Corporation was paid $21.93M by Medicaid between Jan 2018 and Dec 2024, across 177 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.

33Billing provider infoBAYSTATE NOBLE HOSPITAL CORPORATION
WESTFIELD, MA 01085
33aNPI1700816048assigned 07/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.93M
24GClaims559,872
24DCodes billed177
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Massachusetts

Rank by total paid#38 of 66
Median peer was paid$29.11M
This provider vs. median0.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201878,707$3.97M
201978,491$2.34M
202065,947$1.84M
202186,214$2.82M
202297,920$3.84M
202389,636$4.06M
2024incomplete62,957$3.07M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 18% 29,267 27,070 $4.03M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 17% 26,697 24,256 $3.72M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 10% 13,973 12,567 $2.21M
96361 Intravenous infusion, hydration; each additional hour 9.9% 7,091 6,002 $2.17M
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 3.9% 15,868 4,582 $863K
99282 Emergency department visit for the evaluation and management, low to moderate severity 3.6% 6,155 5,854 $783K
74177 Computed tomography, abdomen and pelvis; with contrast material 3.4% 5,764 5,493 $755K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple 3.3% 940 908 $733K
70450 Computed tomography, head or brain; without contrast material 2.9% 5,225 4,903 $644K
S9485 Crisis intervention mental health services, per diem 2.4% 1,105 776 $537K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel 2.0% 7,177 6,448 $433K
74176 Computed tomography, abdomen and pelvis; without contrast material 2.0% 2,034 1,969 $429K
165 more codes
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.4% 3,569 $309K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour 1.1% 1,992 $237K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 6,364 $197K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 36,096 $161K
93971 <1% 1,092 $157K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 1,872 $155K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 4,088 $145K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 2,458 $140K
97161 <1% 2,560 $139K
77063 Screening digital breast tomosynthesis, bilateral <1% 2,410 $133K
71046 Radiologic examination, chest; 2 views <1% 14,298 $133K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 7,103 $131K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 1,967 $130K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 744 $114K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 818 $112K
77067 Screening mammography, bilateral, including computer-aided detection <1% 3,033 $101K
87631 <1% 1,431 $101K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 3,973 $100K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 14,519 $82K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 425 $80K
76830 Ultrasound, transvaginal <1% 774 $78K
84484 <1% 10,982 $71K
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 72 $68K
M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring <1% 243 $67K
G0378 Hospital observation service, per hour <1% 1,861 $66K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 309 $59K
83605 <1% 8,575 $58K
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 81 $52K
83880 <1% 2,829 $51K
J0248 Injection, remdesivir, 1 mg <1% 142 $48K
80048 Basic metabolic panel (calcium, ionized) <1% 14,603 $47K
83690 <1% 11,017 $47K
Q0222 Injection, bebtelovimab, 175 mg <1% 96 $47K
80053 Comprehensive metabolic panel <1% 8,606 $42K
93975 <1% 415 $42K
71275 Computed tomographic angiography, chest, with contrast material <1% 383 $42K
81025 <1% 7,387 $40K
M0247 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring <1% 162 $38K
76770 <1% 283 $34K
87086 Culture, bacterial; quantitative colony count, urine <1% 6,341 $31K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 2,537 $27K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 908 $25K
84443 Thyroid stimulating hormone (TSH) <1% 2,640 $25K
97014 <1% 937 $24K
72100 <1% 1,167 $23K
80051 <1% 13,094 $23K
87088 <1% 2,992 $23K
73030 <1% 1,303 $23K
73630 <1% 1,544 $21K
85379 <1% 3,405 $21K
81001 <1% 10,442 $20K
73562 <1% 544 $19K
73560 <1% 1,311 $19K
87040 <1% 2,922 $18K
96375 Therapeutic injection; each additional sequential IV push <1% 10,850 $18K
73610 <1% 1,507 $18K
ATP14 <1% 1,970 $17K
G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk <1% 13 $16K
83735 <1% 4,345 $16K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 94 $16K
ATP08 <1% 2,386 $15K
71045 Radiologic examination, chest; single view <1% 3,778 $14K
84703 <1% 2,492 $14K
82947 <1% 12,301 $13K
85610 <1% 6,828 $12K
82565 <1% 12,836 $12K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 18,883 $12K
87081 <1% 1,981 $11K
ATP07 <1% 1,587 $11K
84520 <1% 12,775 $10K
70496 <1% 64 $9K
73130 <1% 699 $9K
M0222 Intravenous injection, bebtelovimab, includes injection and post administration monitoring <1% 92 $9K
86140 <1% 2,411 $8K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 5,565 $7K
80076 <1% 2,654 $7K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 125 $7K
70551 Magnetic resonance imaging, brain; without contrast material <1% 60 $6K
81000 <1% 3,126 $6K
73110 <1% 396 $6K
ATP11 <1% 838 $6K
81003 <1% 4,231 $6K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 2,961 $5K
90715 <1% 235 $5K
72125 Computed tomography, cervical spine; without contrast material <1% 770 $5K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 159 $5K
M0239 Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring <1% 29 $5K
84450 <1% 5,496 $5K
94060 <1% 71 $5K
84460 <1% 5,409 $5K
84075 <1% 5,085 $4K
82247 <1% 5,053 $4K
76642 <1% 53 $4K
71250 <1% 56 $4K
ATP15 <1% 502 $4K
76536 <1% 39 $4K
87186 <1% 724 $4K
85027 <1% 951 $4K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 9,499 $4K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 7,677 $3K
96376 <1% 3,858 $3K
87070 <1% 351 $2K
12001 <1% 12 $2K
94729 <1% 70 $2K
73502 <1% 136 $2K
J1170 Injection, hydromorphone, up to 4 mg <1% 2,428 $2K
94726 <1% 57 $2K
82962 <1% 4,310 $1K
87147 <1% 331 $1K
J3490 Unclassified drugs <1% 946 $1K
J2704 Injection, propofol, 10 mg <1% 5,064 $1K
70491 <1% 13 $1K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 448 $1K
81002 <1% 782 $1K
84100 <1% 963 $1K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 38 $1K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 39 $1K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 1,105 $1K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 995 $1K
85730 <1% 352 $1K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 5,859 $966.90
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care <1% 161 $720.94
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 368 $712.95
36415 Collection of venous blood by venipuncture <1% 6,831 $633.09
J2270 Injection, morphine sulfate, up to 10 mg <1% 2,952 $555.44
87103 <1% 92 $508.73
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 1,461 $500.74
J1650 Injection, enoxaparin sodium, 10 mg <1% 106 $452.25
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 14 $395.96
87476 <1% 14 $393.04
73140 <1% 47 $334.28
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 2,637 $213.92
84702 <1% 13 $172.51
86618 <1% 12 $165.22
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 294 $150.21
J0690 Injection, cefazolin sodium, 500 mg <1% 43 $141.47
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 162 $141.47
73590 <1% 12 $132.74
87077 <1% 30 $126.68
ATP09 <1% 23 $125.44
82550 <1% 70 $112.77
82010 <1% 15 $82.06
96367 <1% 17 $56.57
J2060 Injection, lorazepam, 2 mg <1% 986 $54.92
86308 <1% 12 $54.84
73080 <1% 15 $50.65
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 622 $44.39
J1630 Injection, haloperidol, up to 5 mg <1% 161 $1.25
Q0247 Injection, sotrovimab, 500 mg <1% 81 $0.08
A9575 Injection, gadoterate meglumine, 0.1 ml 0% 341 $0.00
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 51 $0.00
80061 Lipid panel 0% 27 $0.00
Q0244 Injection, casirivimab and imdevimab, 1200 mg 0% 49 $0.00
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals 0% 51 $0.00
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg 0% 15 $0.00
94664 0% 27 $0.00
J0780 Injection, prochlorperazine, up to 10 mg 0% 14 $0.00
Q0245 Injection, bamlanivimab and etesevimab, 2100 mg 0% 13 $0.00
J3475 Injection, magnesium sulfate, per 500 mg 0% 12 $0.00
94760 0% 574 $0.00
36416 0% 553 $0.00
G8980 Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting 0% 15 $0.00
70498 0% 24 $0.00
G0008 Administration of influenza virus vaccine 0% 12 $0.00
C9285 Lidocaine 70 mg/tetracaine 70 mg, per patch 0% 15 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWITHERELL, DAVID (SENIOR DIRECTOR, PAYMENT SYSTEMS)